Priscilla Stumpf, MD
Radiation Oncology · Greenfield, INNPI 1013350578
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $653 and has fallen 81.8% since, to $119 in 2025.
Across 75 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$258
- Merck$148
- Eisai Inc.$96
- Johnson & Johnson$92
- Amgen$73
- Seagen Inc.$45
- plus $661 from 25 others
What the payments were for
- Food & beverage$1,374100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $258 |
| Merck | 7 | $148 |
| Eisai Inc. | 5 | $96 |
| Johnson & Johnson(2 entities) | 5 | $92 |
| Amgen | 5 | $73 |
| Seagen Inc. | 2 | $45 |
| Sobi, Inc | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Servier Pharmaceuticals LLC | 2 | $41 |
| AbbVie | 2 | $40 |
| Taiho Oncology, Inc. | 2 | $40 |
| Coherus Oncology, Inc. | 2 | $40 |
| AstraZeneca | 2 | $39 |
| Exelixis Inc. | 2 | $38 |
| Boston Scientific | 2 | $28 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Siemens Medical Solutions USA, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Sanofi | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Legend Biotech USA Inc. | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $19 |
| Genmab U.S., Inc. | 1 | $18 |
| Myovant Sciences Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
| Incyte Corporation | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$1,374 in reported general payments places this provider in the 65th percentile of 116 radiation oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 48 | $408 |
| Dexamethasone | 24 | $266 |
| Mometasone Furoate | 17 | $253 |
| Lorazepam | 13 | $8 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Greenfield
- Brian ChangFort Wayne$13K
- Michael EatonIndianapolis$11K
- William PorterMadison$8K
- Binh TranMishawaka$7K
- Gordon WatsonIndianapolis$6K
- John CoxIndianapolis$5K
- Houman VaghefiGoshen$5K
- Peter GarrettIndianapolis$5K
- Garrett JensenIndianapolis$4K
- Douglas DebenhamNewburgh$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.